RX Insider Trading

Insider Ownership Percentage: 38.45%
Insider Buying (Last 12 Months): C$52,327.95
Insider Selling (Last 12 Months): C$13,720.00

BioSyent Insider Trading History Chart

This chart shows the insider buying and selling history at BioSyent by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioSyent Share Price & Price History

Current Price: C$9.00
Price Change: +0.30 (1.20%)
As of 05/22/2024 06:13 PM ET

This chart shows the closing price history over time for RX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

BioSyent Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/29/2024BioSyent Inc.InsiderBuy5,100C$8.55C$43,627.95
3/28/2024Larry AndrewsDirectorBuy1,000C$8.70C$8,700.00
3/26/2024Peter Douglas LockhardDirectorSell600C$8.70C$5,220.00
11/27/2023Seyed Ahmad AshrafiDirectorSell1,000C$8.50C$8,500.00
6/30/2022Blair DriscollInsiderBuy25,000C$7.79C$194,750.002,146,100
3/24/2022Sharan RaghubirSenior OfficerSell5,193C$7.63C$39,622.5911,229
See Full Table

SEC Filings (Institutional Ownership Changes) for BioSyent (CVE:RX)

1.37% of BioSyent stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

BioSyent logo
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.
Read More on BioSyent

Today's Range

Now: C$9.00
Low: C$8.95
High: C$9.07

50 Day Range

MA: C$8.60
Low: C$8.24
High: C$9.00

52 Week Range

Now: C$9.00
Low: C$7.03
High: C$9.26

Volume

24,540 shs

Average Volume

6,466 shs

Market Capitalization

C$104.31 million

P/E Ratio

16.98

Dividend Yield

2.12%

Beta

0.93

Who are the company insiders with the largest holdings of BioSyent?

BioSyent's top insider shareholders include:
  1. Blair Driscoll (Insider)
  2. BioSyent Inc (Insider)
  3. Larry Andrews (Director)
  4. Peter Douglas Lockhard (Director)
  5. Seyed Ahmad Ashrafi (Director)
Learn More about top insider investors at BioSyent.